Murjne Anti‐Idiotypic Monoclonal Antibodies to Syngeneic Antihuman High Molecular Weight‐Melanoma Associated Antigen Monoclonal Antibodies: Development, Characterization, and Clinical Applications

Kageshita, Toshiro; Chen, Zhi Jian; Kim, Jin-Woo; Kusama, Mikihiro; Kekish, Ulana; Trujillo, Tracy; Temponi, Massimo; Mittelman, Abraham; Ferrone, Soldano

doi:10.1111/j.1600-0749.1988.tb00811.x

Cited by 11 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar Ab-3 response was also seen in CRC patients receiving a goat polyclonal anti-Id specific for the monoclonal Ab-1 to the CRC antigen. An anti-anti-Id (Ab-3) response has also been reported in melanoma patients receiving a monoclonal anti-Id [15]. Tumor-associated Id networks have also been described in a number of animal systems that examine both human and murine tumor-associated antigens.…”

Section: Discussionmentioning

confidence: 93%

Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen

Mernaugh

Shearer

Bright

et al. 1992

Cancer Immunol Immunother

View full text Add to dashboard Cite

Baculovirus-derived recombinant simian virus 40 (SV40) large tumor antigen (SV40 T-Ag), a monoclonal antibody specific for SV40 T-Ag (Ab-1 preparation), and a monoclonal anti-idiotypic antibody (anti-Id), designated 58D, were used to analyze the humoral immune response of Balb/c mice either immunized with recombinant SV40 T-Ag or challenged with SV40-transformed cells. Inhibition assays indicated that antibodies from mice immunized with SV40 T-Ag and from those bearing SV40 tumor inhibited the SV40 T-Ag/Ab-1 reaction. These data suggested that the antibody response in immunized or tumor-challenged mice recognized similar epitope(s) on SV40 T-Ag to that detected by the monoclonal Ab-1. These anti-(SV40 T-Ag) response antibodies also inhibited the Ab-1/anti-Id reaction and recognized the anti-Id in direct binding assays. Together, these data indicate that murine anti-(SV40 T-Ag) responses shared an idiotope with a monoclonal anti-(SV40 T-Ag) Ab-1 preparation. This idiotope, which is recognized by the monoclonal anti-Id preparation, 58D, appears to be involved in the humoral immune response to SV40 T-Ag in both SV40-T-Ag-immunized and tumor-bearing mice. The monoclonal anti-Id preparation may represent a focal point for manipulating the humoral immune response to tumors induced by SV40-transformed cells.

show abstract

Section: Discussionmentioning

confidence: 93%

Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen

Mernaugh

Shearer

Bright

et al. 1992

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…In order to test the usefulness of mouse antiidiotypic MAb elicited with syngeneic anti-TAA MAb to implement active specific immunotherapy, we have selected malignant melanoma as our model system for a number of reasons (7). First, a therapeutic approach based on manipulation of the patient's immune response has a potential for success in this disease because ofthe likely role of immunological factors in its pathogenesis and in its clinical course (8).…”

mentioning

confidence: 99%

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Mittelman¹,

Chen²,

Kageshita³

et al. 1990

J. Clin. Invest.

122

View full text Add to dashboard Cite

IntroductionIn two clinical trials the mouse antiidiotypic monoclonal antibody (MAb) MF1 1-30, which bears the internal image of human high-molecular-weight-melanoma-associated antigen (HMW-MAA) was administered by subcutaneous route without adjuvants to patients with stage IV malignant melanoma on day 0, 7, and 28. The development of monoclonal antibodies to human tumorassociated antigens (TAA)' that meet the criteria to be used as targets for immunotherapy (for review, see 1-3) has rekindled interest in the application of immunotherapeutic approaches to malignant diseases. Among them, the use of antiidiotypic antibodies, i.e., antibodies to determinants expressed on the variable region of anti-TAA antibodies, is attracting much attention, since in animal model systems the immune response induced by this type of active specific immunotherapy is associated with an improvement of the course of the disease (4-6). The rationale underlying this approach is represented by the ability ofantiidiotypic antibodies that bear the mirror image of TAA to elicit and/or enhance anti-TAA immune responses; such responses may eventually result in the destruction of tumor cells.In order to test the usefulness of mouse antiidiotypic MAb elicited with syngeneic anti-TAA MAb to implement active specific immunotherapy, we have selected malignant melanoma as our model system for a number of reasons (7). First, a therapeutic approach based on manipulation of the patient's immune response has a potential for success in this disease because ofthe likely role of immunological factors in its pathogenesis and in its clinical course (8). Second, testing of a novel therapeutic approach finds justification in the lack of progress and limited success of available therapeutic modalities in malignant melanoma (9). Third, utilizing mouse MAb, we have identified a membrane-bound melanoma-associated antigen, referred to as HMW-MAA (high-molecular-weight-melanoma-associated antigen). This antigen represents a useful target for active and passive immunotherapy because of its high frequency in melanoma lesions, its limited heterogeneity in melanoma lesions, its high density on melanoma cells, and its restricted distribution in normal tissues (for review, see 10). Fourth, we have availability to use the mouse antiidiotypic MAb MFI 1-30 to an idiotope within the antigen-combining site of the syngeneic anti-HMW-MAA MAb 225.28. This antiidiotypic MAb bears the mirror image of HMW-MAA, because it induces anti-HMW-MAA antibodies in allogeneic and xenogeneic combinations (Chattopadhyay, P., S. V. Kaveri, J. Rosenberg, N. Byars, J. Starkey, S. Ferrone, and S. Raychadhuri. Submitted for publication.) The aim of this paper is to describe the results of two clinical trials with anti-1. Abbreviations used in this paper: HMW-MAA, high-molecularweight-melanoma-associated antigen; PBS-T20, PBS supplemented with 0.05% Tween 20; TAA, tumor-associated antigen.

show abstract

Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors

O'Connell

Chen

Yang

et al. 1989

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Tumor-associated antigens (TAA) provide appropriate targets for selective manipulation of the patient's immune response in the immunotherapy of cancer. Active specific immunotherapy utilizing antiidiotypic antibodies to anti-TAA antibodies has been implemented in phase I clinical trials both in patients with colorectal carcinoma and in those with melanoma. The theoretical basis for immunotherapy with antiidiotypic antibodies, the results of these clinical trials, and an evaluation of appropriate parameters for future clinical trials of active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors are reviewed.

show abstract

Murjne Anti‐Idiotypic Monoclonal Antibodies to Syngeneic Antihuman High Molecular Weight‐Melanoma Associated Antigen Monoclonal Antibodies: Development, Characterization, and Clinical Applications

Cited by 11 publications

References 21 publications

Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen

Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors

Contact Info

Product

Resources

About